Log in

Relevant bibliographies by topics / SIGLICA

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'SIGLICA'

Author: Grafiati

Published: 4 June 2021

Last updated: 10 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'SIGLICA.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "SIGLICA"

1

Zid, Mouldi, and Guy Drouin. "Gene conversions are frequent but not under positive selection in the Siglec gene families of primates." Genome 57, no. 6 (2014): 317–25. http://dx.doi.org/10.1139/gen-2014-0083.

Full text

Abstract:

Siglecs are cell surface proteins that belong to the immunoglobulin superfamily and which bind sialic acids. They are composed of two groups, the conserved Siglecs and the CD33-related Siglecs. Previous studies have reported the occurrence of gene conversions between human CD33-related Siglecs and suggested that these conversions are adaptive because they increase the diversity of these immunoglobulin-related genes. Here, we analyze the Siglec genes of five primate species and show that gene conversions are not observed between conserved Siglec genes but that they are frequent between primate CD33-related Siglecs. The gene conversions between CD33-related Siglec genes only occur between similar genes and equally frequently in sialic acid binding and nonbinding domains. Furthermore, dN/dS ratio tests show that most of the Ig-like V-type 1 and the Ig-like C2-type 1 domains of Siglec genes evolve either neutrally or under purifying selection and that gene conversions were not responsible for the positively selected regions detected in the Ig-like V-type1 domain of the human SIGLEC7 and SIGLEC9 genes. Our results suggest that the frequent gene conversions between CD33-related Siglec genes are simply a consequence of the high degree of sequence similarity of these genes and that they are not adaptive.

APA, Harvard, Vancouver, ISO, and other styles

2

Malhotra, S., J. Castilló, MF Bustamante, et al. "SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis." Multiple Sclerosis Journal 19, no. 5 (2012): 524–31. http://dx.doi.org/10.1177/1352458512458718.

Full text

Abstract:

Background: Sialic acid binding immunoglobulin-like lectins (Siglecs) are cell surface receptors that recognize sialic acids and may attenuate immune responses and reduce inflammation. Objective: The purpose of this study was to investigate the role of two members of the Siglec family, SIGLEC1 and SIGLEC7, in the clinical course and disease activity of patients with multiple sclerosis (MS). Methods: SIGLEC1 and SIGLEC7 expression was determined by flow cytometry in the blood monocytes of 16 healthy controls and 55 untreated MS patients (13 primary progressive MS (PPMS) patients, 13 secondary progressive MS (SPMS) patients and 29 relapsing–remitting MS (RRMS) patients (18 during clinical remission and 11 during relapse)). Results: SIGLEC1 expression by CD14+ monocytes was significantly increased in MS patients compared with controls ( p=0.025 for percentage of positive cells; p=0.007 for mean fluorescence intensity (MFI)). Stratification of patients into different clinical forms revealed increased SIGLEC1 expression in patients with progressive forms of the disease, particularly in those with PPMS ( p=0.003 for percentage of positive cells and p=0.001 for MFI when compared with controls; p=0.031 for percentage of positive cells when compared with RRMS patients). Both inflammatory and resident monocytes contributed to the increase in SIGLEC1 expression observed in PPMS patients. SIGLEC7 expression was significantly up-regulated in blood monocytes from RRMS during relapse compared with patients during clinical remission ( p=0.001 for MFI). Conclusions: These findings suggest roles for SIGLEC1 in the chronic progressive phases of MS and for SIGLEC7 in acute disease activity.

APA, Harvard, Vancouver, ISO, and other styles

3

Zheng, Yayun, Xue Ma, Dongmei Su, et al. "The Roles of Siglec7 and Siglec9 on Natural Killer Cells in Virus Infection and Tumour Progression." Journal of Immunology Research 2020 (April 6, 2020): 1–9. http://dx.doi.org/10.1155/2020/6243819.

Full text

Abstract:

The function of natural killer (NK) cells, defending against virus infection and tumour progression, is regulated by multiple activating and inhibiting receptors expressed on NK cells, among which sialic acid-bind immunoglobulin-like lectins (Siglecs) act as a vital inhibitory group. Previous studies have shown that Siglec7 and Siglec9 are expressed on NK cells, which negatively regulate the function of NK cells and modulate the immune response through the interaction of sialic acid-containing ligands. Siglec7 and Siglec9 are very similar in distribution, gene encoding, protein sequences, ligand affinity, and functions in regulating the immune system against virus and cancers, but differences still exist between them. In this review, we aim to discuss the similarities and differences between Siglec7 and Siglec9 and analyze their functions in virus infection and tumour progression in order to develop better anti-viral and anti-tumor immunotherapy in the future.

APA, Harvard, Vancouver, ISO, and other styles

4

Siddiqui, Shoib Sarwar, Rachel Matar, Maxime Merheb, et al. "Siglecs in Brain Function and Neurological Disorders." Cells 8, no. 10 (2019): 1125. http://dx.doi.org/10.3390/cells8101125.

Full text

Abstract:

Siglecs (Sialic acid-binding immunoglobulin-type lectins) are a I-type lectin that typically binds sialic acid. Siglecs are predominantly expressed in immune cells and generate activating or inhibitory signals. They are also shown to be expressed on the surface of cells in the nervous system and have been shown to play central roles in neuroinflammation. There has been a plethora of reviews outlining the studies pertaining to Siglecs in immune cells. However, this review aims to compile the articles on the role of Siglecs in brain function and neurological disorders. In humans, the most abundant Siglecs are CD33 (Siglec-3), Siglec-4 (myelin-associated glycoprotein/MAG), and Siglec-11, Whereas in mice the most abundant are Siglec-1 (sialoadhesin), Siglec-2 (CD22), Siglec-E, Siglec-F, and Siglec-H. This review is divided into three parts. Firstly, we discuss the general biological aspects of Siglecs that are expressed in nervous tissue. Secondly, we discuss about the role of Siglecs in brain function and molecular mechanism for their function. Finally, we collate the available information on Siglecs and neurological disorders. It is intriguing to study this family of proteins in neurological disorders because they carry immunoinhibitory and immunoactivating motifs that can be vital in neuroinflammation.

APA, Harvard, Vancouver, ISO, and other styles

5

Mitic, N., B. Milutinovic, and M. Jankovic. "Assessment of Sialic Acid Diversity in Cancer- and Non-Cancer Related CA125 Antigen Using Sialic Acid-Binding Ig-Like Lectins (Siglecs)." Disease Markers 32, no. 3 (2012): 187–94. http://dx.doi.org/10.1155/2012/309203.

Full text

Abstract:

This study was aimed at obtaining insight into the diversity of sialic acids in cancer- and non-cancer-related CA125 antigen, tumour marker of serous ovarian cancer. Starting from available data suggesting the possible relevance of sialic acids for discriminating CA125 antigens of different origin, we have employed a new experimental approach based on the use of human sialic acid-binding Ig-like lectins, Siglecs, as tools for the investigation of sialylation.Siglec−2, belonging to the group of evolutionarily conserved Siglecs, and Siglec−3, −6, −7, −9 and −10, which are CD33-like Siglecs, were probed in solid-phase binding assays with cancer-related CA125 antigens from pleural fluid of patients with ovarian carcinoma (pfCA125), the OVCAR-3 ovarian carcinoma cell line (clCA125) and a non-cancer-related CA125 antigen, i.e. pregnancy-associated pCA125 antigen.All Siglecs used showed detectable binding to pCA125 antigen. Siglec−3, Siglec−7 and Siglec−2 exhibited moderately stronger binding to pCA125 antigen than the others. In contrast to this, Siglec−2 and Siglec−3 preferentially recognized pfCA125 with greater total binding than for pCA125, whereas Siglec−9 and Siglec−10 were highly selective for clCA125.Siglecs promise to be powerful tools for discriminating CA125 of different origin and could propagate further research on other molecular markers of biomedical and diagnostic importance.

APA, Harvard, Vancouver, ISO, and other styles

6

Pegon, Julie N., Cécile V. Denis, Soline Odouard, Olivier D. Christophe, and Peter J. Lenting. "Siglecs as Novel Cellular Partners for Von Willebrand Factor." Blood 116, no. 21 (2010): 4306. http://dx.doi.org/10.1182/blood.v116.21.4306.4306.

Full text

Abstract:

Abstract Abstract 4306 Introduction: Von Willebrand factor (VWF) is a multimeric protein that is pertinent to the haemostatic process by promoting platelet recruitment to the growing thrombus and acting as a carrier-protein for factor VIII. It is well established that VWF is able to interact with several cellular receptors present on the surface of platelets and leukocytes. In search for novel cellular partners for VWF present on these cells, we made use of the notion that VWF is heavily glycosylated, with the mature molecule containing 12 N-linked glycans and 10 O-linked glycans. Importantly, the vast majority of these glycans (>90%) are sialylated. The human proteome contains a family of sialic acid-binding receptors, known as Sialic acid-binding Immunoglobulin-like Lectins (Siglecs), which are expressed on cells of hematopoietic origin. The current study was designed to investigate the potential of Siglecs to interact with VWF. Methods: Stable human HEK293 cell lines were established that express human Siglec-5, Siglec-7 or Siglec-9. In addition, soluble variants of Siglecs were obtained: monomeric HPC4-tagged Siglec-5 and Siglec-7 (sSg5/HPC4 & sSg7/HPC4) and dimeric Fc-fusion proteins for human Siglec-3, -5, -7, -9, -10, -11 and murine Siglec-F (sSg-3/Fc etc). These Siglecs were used to study their interaction with purified plasma-derived (pdVWF) or recombinant BHK-cell derived VWF (rVWF). Protein-protein interactions were investigated via immuno-sorbent assays and via surface plasmon resonance (SPR) using Octet QK equipment. Binding of VWF to Siglec-expressing cells was assessed via immuno-fluorescence microscopy. Results: We observed consistent association of VWF (irrespective whether immuno-sorbent or SPR assays were used) to all of the immobilized Siglecs tested, with the exception of sSg-11/Fc that did not interact with pdVWF or with rVWF. Inversely, all soluble Siglecs but sSg-11/Fc efficiently bound to immobilized pdVWF or rVWF. Half-maximal binding in immuno-sorbent assays was between 97 and 645 nM (binding of VWF to immobilized Siglecs) versus 166 and 270 nM (binding of Siglecs to immobilized VWF). More detailed studies on the determination of the kinetic parameters using SPR technology are in progress. Specificity of the interaction was confirmed by treating VWF with sialidase before testing Siglec binding, and such treatment resulted in a strongly reduced (up to 80%) ability of Siglecs to bind to immobilized VWF. VWF was further found to bind to Siglec-5, -7 or -9 expressing HEK293 cells as assessed via immuno-fluorescence microscopy. In general, 10–15 % of the Siglec-expressing cells were covered with VWF after incubation, with the fluorescent intensity increasing dose-dependently with the applied VWF concentration. No fluorescent signal was observed upon incubation of VWF with non-transfected cells or when VWF was omitted from the incubation. Since Siglecs may be masked by the presence of endogenous sialylated proteins at the cellular surface, we also tested VWF binding to these cells following sialidase treatment. Sialidase treatment of cells resulted in a marked increase in the number of VWF-binding cells (up to 80% of the Siglec-positive cells) as well as an increase in intensity of the fluorescent signal. Co-localization of VWF with Siglecs at the cellular surface was confirmed by DuoLink-analysis, which allows the detection of proteins that are in the vicinity of ≤40 nm. Emerging evidence demonstrates that endothelial. Conclusions: We identified one murine and six human Siglec-family members as novel partners for VWF. Interactions between VWF and Siglecs are mediated by sialic acid structures present on VWF. In addition, the cellular accessibility of Siglecs for VWF is modulated by cis-acting sialylated proteins at the cell surface. In conclusion, our data demonstrate that the VWF glycome allows the interaction with a novel family of cellular receptors, potentially opening previously unrecognized avenues in the biology of VWF. Disclosures: No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

7

Avril, T., H. Attrill, J. Zhang, A. Raper, and P. R. Crocker. "Negative regulation of leucocyte functions by CD33-related siglecs." Biochemical Society Transactions 34, no. 6 (2006): 1024–27. http://dx.doi.org/10.1042/bst0341024.

Full text

Abstract:

The siglecs (sialic acid-binding Ig-like lectins) are a family of transmembrane receptors expressed in the haemopoietic, immune and nervous systems. The CD33-related siglecs are a distinct subset mostly expressed in the innate immune system where they can function as inhibitory receptors by suppressing the signalling mediated by receptors coupled with ITAMs (immunoreceptor tyrosine-based activation motifs). CD33-related siglecs contain ITIMs (immunoreceptor tyrosine-based inhibitory motifs) that recruit and activate SHP-1 [SH2 (Src homology 2) domain-containing phosphatase-1] and SHP-2. In addition, the ITIMs of CD33-related siglecs can suppress siglec-dependent adhesion of sialylated ligands and mediate endocytosis. Siglec-H is a recently characterized murine CD33-related endocytic receptor that lacks intrinsic tyrosine-based signalling motifs and is expressed selectively on PDCs (plasmacytoid dendritic cells). Siglec-H depends on DAP12 (DNAX-activating protein of 12 kDa) for surface expression and cross-linking with anti-siglec-H antibodies can selectively inhibit interferon-α production by PDCs following TLR9 (Toll-like receptor 9) ligation. Thus CD33-related siglecs are able to mediate diverse inhibitory functions of leucocytes in the innate immune system via both ITIM-dependent and -independent pathways.

APA, Harvard, Vancouver, ISO, and other styles

8

Crocker, Paul R., and Pierre Redelinghuys. "Siglecs as positive and negative regulators of the immune system." Biochemical Society Transactions 36, no. 6 (2008): 1467–71. http://dx.doi.org/10.1042/bst0361467.

Full text

Abstract:

Siglecs (sialic acid-binding Ig-like lectins) are mainly expressed in the immune system. Sn (sialoadhesin) (siglec-1), CD22 (siglec-2) and siglec-15 are well conserved, whereas the CD33-related siglecs are undergoing rapid evolution, as reflected in large differences in repertoires among the different mammals studied so far. In the present paper, we review recent findings on the signalling properties of the CD33-related siglecs and discuss the emergence of both inhibitory and activating forms of this family. We also discuss how Sn may function as a positive regulator of adaptive immune responses and its emerging role as an induced macrophage pattern-recognition molecule for sialylated pathogens, especially enveloped viruses.

APA, Harvard, Vancouver, ISO, and other styles

9

Attrill, Helen, Hirokazu Takazawa, Simone Witt, et al. "The structure of siglec-7 in complex with sialosides: leads for rational structure-based inhibitor design." Biochemical Journal 397, no. 2 (2006): 271–78. http://dx.doi.org/10.1042/bj20060103.

Full text

Abstract:

Siglecs (sialic acid binding Ig-like lectins) are transmembrane receptors for sialylated glycoconjugates that modulate cellular interactions and signalling events in the haematopoietic, immune and nervous systems. Siglec-7 is a structural prototype for the recently described family of immune inhibitory CD33-related siglecs and is predominantly expressed on natural killer cells and monocytes, as well as subsets of CD8 T-cells. Siglec-specific inhibitors are desired for the detection of masked and unmasked forms of siglecs, to aid in dissection of signalling pathways and as tools to investigate siglecs as potential therapeutic targets. As a first step towards this end, we present the crystal structure of siglec-7 in complex with a sialylated ligand, the ganglioside analogue DSLc4 [α(2,3)/α(2,6) disialyl lactotetraosyl 2-(trimethylsilyl)ethyl], which allows for a detailed description of the binding site, required for structure-guided inhibitor design. Mutagenesis and binding assays were used to demonstrate a key structural role for Lys131, a residue that changes conformation upon sialic acid binding. Differences between the binding sites of siglec family members were then exploited using α-methyl Neu5Ac (N-acetylneuraminic acid) as a basic scaffold. A co-crystal of siglec-7 in complex with the sialoside inhibitor, oxamido-Neu5Ac [methyl α-9-(amino-oxalyl-amino)-9-deoxy-Neu5Ac] and inhibition data for the sialosides gives clear leads for future inhibitor design.

APA, Harvard, Vancouver, ISO, and other styles

10

Lenza, María Pia, Unai Atxabal, Iker Oyenarte, Jesús Jiménez-Barbero, and June Ereño-Orbea. "Current Status on Therapeutic Molecules Targeting Siglec Receptors." Cells 9, no. 12 (2020): 2691. http://dx.doi.org/10.3390/cells9122691.

Full text

Abstract:

The sialic acid-binding immunoglobulin-type of lectins (Siglecs) are receptors that recognize sialic acid-containing glycans. In the majority of the cases, Siglecs are expressed on immune cells and play a critical role in regulating immune cell signaling. Over the years, it has been shown that the sialic acid-Siglec axis participates in immunological homeostasis, and that any imbalance can trigger different pathologies, such as autoimmune diseases or cancer. For all this, different therapeutics have been developed that bind to Siglecs, either based on antibodies or being smaller molecules. In this review, we briefly introduce the Siglec family and we compile a description of glycan-based molecules and antibody-based therapies (including CAR-T and bispecific antibodies) that have been designed to therapeutically targeting Siglecs.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "SIGLICA"

1

Munday, James. "The characterisation and functional analysis of sialoadhesin (siglec-1) and novel siglecs expressed on mononuclear phagocytes." Thesis, University of Oxford, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.302126.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Boyd, C. R. "Regulation of microbial responses by siglecs." Thesis, Queen's University Belfast, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.516867.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Malhotra, Sunny 1984. "Search of prognostic biomarkers in patients with multiple sclerosis." Doctoral thesis, Universitat Pompeu Fabra, 2014. http://hdl.handle.net/10803/129852.

Full text

Abstract:

The aim of the thesis was to identify biomarkers for multiple sclerosis (MS) prognosis, in particular disease activity biomarkers and interferon-β (IFNβ) treatment response biomarkers. The results presented in this thesis show an increase in the expression of sialic acid binding Ig-like lectins 1 (SIGLEC1) in progressive phases of MS (particularly during primary progressive MS - PPMS). Detailed analysis has demonstrated that both inflammatory and resident monocytes contributed to increased SIGLEC1 expression in PPMS. We also reported that SIGLEC7 expression was elevated in relapsing-remitting MS (RRMS) patients during relapses. Our results also indicate deficient expression of ubiquitin specific peptidase 18 (USP18) in RRMS patients as compared to controls. Further investigation revealed that haplotype CG carriers showed lower USP18 gene expression levels and higher clinical disease activity compared to CG non-carriers. Moreover, AA homozygosis for an intronic polymorphism of USP18 was associated with the responder phenotype. In conclusion, our results suggest the implication of SIGLEC1 in chronic progressive phases of MS and of SIGLEC7 in acute disease activity. We also demonstrated the implication of USP18 in MS pathogenesis and the therapeutic response to IFNβ. Based on these results, we propose SIGLEC1, SIGLEC7 and USP18 as potential disease activity biomarkers of MS, and USP18 as response biomarker to IFNβ.<br>El objetivo de esta tesis ha sido la identificación de biomarcadores pronósticos en la esclerosis múltiple (EM), principalmente biomarcadores de actividad de la enfermedad y biomarcadores de respuesta al tratamiento con interferón beta (IFNβ). Los resultados expuestos en esta tesis muestran un incremento en la expresión del gen “sialic acid binding Ig-like lectins 1” (SIGLEC1) en fases progresivas de la EM (principalmente en pacientes con EM primariamente progresiva - EMPP). Un análisis más detallado demostró que tanto los monocitos residentes como los inflamatorios contribuyeron al incremento de la expresión de SIGLEC1 en pacientes con EMPP. También observamos que la expresión de SIGLEC7 se encuentró aumentada en la EM recurrente-remitente (EMRR) durante el brote. Nuestros resultados también mostraron una expresión deficiente del gen “ubiquitin specific peptidase 18” (USP18) en pacientes con EMRR comparado con controles. Experimentos adicionales mostraron que los pacientes portadores del haplotipo CG presentaron niveles de expresión del gen USP18 disminuidos y un incremento en la actividad clínica de la enfermedad en comparación con los no portadores del haplotipo CG. Además, los pacientes homocigotos AA para un polimorfismo intrónico del gen USP18 presentaron una buena respuesta al tratamiento con IFNβ. En conclusión, nuestros resultados sugieren la implicación de SIGLEC1 en la fase crónica progresiva de la EM, y un papel de SIGLEC7 en la actividad aguda de la enfermedad. También sugieren la implicación de USP18 en la patogenia de la EM y la respuesta terapéutica al IFNβ. En base a estos resultados, proponemos SIGLEC1, SIGLEC7 y USP18 como biomarcadores de actividad de la enfermedad, y USP18 como biomarcador de respuesta al IFNβ.

APA, Harvard, Vancouver, ISO, and other styles

4

Kopatz, Jens Christopher [Verfasser]. "Microglial sialic-acid-binding immunoglobulin-like lectin-H (Siglec-H) and Siglec-11 in neuroinflammation / Jens Christopher Kopatz." Bonn : Universitäts- und Landesbibliothek Bonn, 2015. http://d-nb.info/1081423676/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kopatz, Jens [Verfasser]. "Microglial sialic-acid-binding immunoglobulin-like lectin-H (Siglec-H) and Siglec-11 in neuroinflammation / Jens Christopher Kopatz." Bonn : Universitäts- und Landesbibliothek Bonn, 2015. http://d-nb.info/1081423676/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Carlin, Aaron Foster. "Siglec interactions with a sialylated bacterial pathogen." Diss., Connect to a 24 p. preview or request complete full text in PDF format. Access restricted to UC campuses, 2007. http://wwwlib.umi.com/cr/ucsd/fullcit?p3263070.

Full text

Abstract:

Thesis (Ph. D.)--University of California, San Diego, 2007.<br>Title from first page of PDF file (viewed April 9, 2008). Available via ProQuest Digital Dissertations. Vita. Includes bibliographical references.

APA, Harvard, Vancouver, ISO, and other styles

7

Cao, H. "Functions, evolution and therapeutic potential of novel activating Siglecs." Thesis, University of Cambridge, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.597276.

Full text

Abstract:

The Sialic acid binding immunoglobulin-like lectins (Siglecs) are important components of immune recognition. Comparative genomics showed that <i>SIGLEC11 </i>genes underwent dynamic gene duplication and conversion, forming a potentially inhibitory (<i>SIGLEC11</i>)/activating (<i>SIGLEC16</i>) receptor pair in chimpanzees and humans. I identified full-length cDNA of human <i>SIGLEC16, </i>previously classed as a pseudogene (<i>SIGLECP16</i>). A UK based polymorphism screen for the two alleles, one functional and the other a pseudogene, of <i>SIGLEC16 </i>indicated that they are present at a similar frequency. Using Siglec-16 specific antisera, I identified Siglec-16 protein in normal human brain, and esophageal and lung tumours. An extensive comparative genomic analysis of the CD33rSiglec cluster was carried out to understand the evolution of other activating Siglecs. The CD33rSiglec cluster could be divided into two subclusters, inverted relative to each other. Two regions of strong correspondence provided evidence for a large-scale inverse duplication over 180 million years ago. Activating Siglecs appear to have arisen rapidly in primates but subsequently underwent de-selection. <i>SIGLEC15 </i>is evolutionarily conserved and its sequence is distinct from those of other members of the Siglec family. I raised A9E8, a phage display monoclonal antibody specific to Siglec-15. I found low surface expression on healthy leukocytes, including T cells, monocytes, macrophages and dendritic cells. However, expression was much higher on blasts of acute myeloid leukaemia (AML) patients. I detected prominent Siglec-15 expression in an AML patient who was negative for CD33, a common target in the treatment of AML. Siglec-15 therefore has potential as a novel target for AML treatment. Experiments showed that Siglec-15 is rapidly endocytosed, suggesting that it may be exploited for introducing toxins into leukaemic cells.

APA, Harvard, Vancouver, ISO, and other styles

8

Orr, S. J. "Regulation of expression and function of CD33-related siglecs." Thesis, Queen's University Belfast, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.432514.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

García, Pérez Angela. "Investigation of Siglec8 as a therapeutic target to treat asthma." Thesis, University of Warwick, 2018. http://wrap.warwick.ac.uk/109203/.

Full text

Abstract:

Siglecs (Sialic Acid Immunoglobulin-like Lectins) are immune system protein receptors that play important roles in the down-regulation of cellular signals upon Sialic Acid ligand binding. At present, the human Siglec family is composed of 16 members expressed by specific immune system cellular types. Due to their highly restrictive expression patterns and key regulatory function, Siglecs have been pointed out as interesting pharmaceutical targets to treat certain immune diseases where those specific cellular types are involved. This work is focused on Siglec8 which is expressed on the surface of mast cells and eosinophils and has demonstrated to induce their apoptosis upon ligand binding. This effect could be exploited to develop therapeutics that target and reduce the levels of eosinophils in the inflammatory diseases such as asthma where they are the main effectors. The aim of this thesis is to design some Siglec8-ligand mimetic small molecules, test their binding to the receptor and obtain affinity data about the interaction. We managed to express the Siglec8 Ig-like V-type carbohydrate binding domains in Escherichia coli, refold and purify them in solution and perform a biophysical characterization by means of different techniques such as Fluorescence, Absorbance, Mass Spectrometry (MS), Circular Dichroism (CD) and Single-Angle Neutron Scattering (SAXS). We also designed nine small Siglec8-ligand mimetic molecules and tested their binding to the receptor domains using the Octet technology and equilibrium dialysis-1 D H+ NMR measurements. We found the ligand Phospho-Tyrosine to be our best Siglec8 binder and estimated a dissociation constant around 100 μM for the interaction. Thus, the binding information obtained in this work could lead to the development of higher affinity and specific molecules that target Siglec8. This thesis also encompassed an industrial collaboration with the company Mologic Ltd where anti-Siglec8 antibodies where developed with chronic lung disease diagnostic purposes.

APA, Harvard, Vancouver, ISO, and other styles

10

Sigloch, Helene [Verfasser], and Matthias [Akademischer Betreuer] Wendt. "Homotopy theory for rigid analytic varieties / Helene Sigloch ; Betreuer: Matthias Wendt." Freiburg : Albert-Ludwigs-Universität Freiburg, 2016. http://d-nb.info/112692153X/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "SIGLICA"

1

Abadilla, Bayani S. Sigliwa kamao. Prometheus Pub., 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Lowe, Ronald. Siglit Inuvialuit Ilisarviksait: Basic Siglit Inuvialuit Eskimo grammar. Committee for Original Peoples Entitlement, 1985.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Lowe, Ronald. Siglit Inuvialuit uqautchiita nutaat kipuktirutait aglipkaqtat =: Siglit Inuvialuit Eskimo dictionary. 2nd ed. Éditions Nota bene, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Bertelsson, Þráinn. Sigla himinfley: Skáldsaga. Skjaldborg, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Olsen, Óli. Sigling og útbúgving: Frá landnámi til okkara dagar. Kjølur, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ribeiro, Tirzah. A sigla do silêcio: Poesias. Ediciones La Urpila, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Tapia-Rano, Osvaldo de. La Habana en el siglio xxi: Urbanismo actual. Ediciones Universal, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Landau, Elaine. Osama bin Laden: El terrorismo del sigla XXI. Planeta, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

McNamee, Kathleen. Sigla and select marginalia in Greek literary papyri. Fondation Égyptologique Reine Élisabeth, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Foussias, George. Identification, characterization, and mapping of novel members of the siglec family. National Library of Canada, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "SIGLICA"

1

Angata, Takashi, and Ajit Varki. "Siglec Siglecs Interactions with Pathogens Pathogens." In Glycoscience: Biology and Medicine. Springer Japan, 2014. http://dx.doi.org/10.1007/978-4-431-54841-6_211.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Gupta, G. S. "CD33 (Siglec 3) and CD33-Related Siglecs." In Animal Lectins: Form, Function and Clinical Applications. Springer Vienna, 2012. http://dx.doi.org/10.1007/978-3-7091-1065-2_17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Gressner, A. M., and O. A. Gressner. "Siglec-1." In Springer Reference Medizin. Springer Berlin Heidelberg, 2019. http://dx.doi.org/10.1007/978-3-662-48986-4_3784.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Gressner, A. M., and O. A. Gressner. "Siglec-1." In Lexikon der Medizinischen Laboratoriumsdiagnostik. Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-662-49054-9_3784-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

de Faveri, Lorena. "Sigla." In Die metrischen Trikliniusscholien zur byzantinischen Trias des Euripides. J.B. Metzler, 2002. http://dx.doi.org/10.1007/978-3-476-02880-8_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Varki, A. "Siglecs." In Encyclopedia of Biological Chemistry. Elsevier, 2013. http://dx.doi.org/10.1016/b978-0-12-378630-2.00483-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Kelm, S., and R. Ravindran. "Siglecs." In Comprehensive Glycoscience. Elsevier, 2007. http://dx.doi.org/10.1016/b978-044451967-2/00064-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Varki, Ajit. "Siglecs." In Encyclopedia of Biological Chemistry. Elsevier, 2004. http://dx.doi.org/10.1016/b0-12-443710-9/00624-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Oetke, Cornelia, and Paul Crocker. "Siglecs." In Animal Lectins. CRC Press, 2008. http://dx.doi.org/10.1201/9781420006971.pt5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

"Sigla Sigla Sigles." In Sprachphilosophie / Philosophy of Language / La philosophie du langage, edited by Marcelo Dascal, Dietfried Gerhardus, Kuno Lorenz, and Georg Meggle. Walter de Gruyter, 1995. http://dx.doi.org/10.1515/9783110139914.2.1763.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "SIGLICA"

1

Orak, Banu, Marc Nikolaus, Ellen Knierim, et al. "AB1168 SIGLEC1/CD169 IS A SENSITIVE MARKER FOR MONOGENIC INTERFERONOPATHIES." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.5506.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

F. M. B. Melo, Victor, Liane M. de Oliveira, Letycia De L. Medeiros, and Gilielson F. da Paz. "Comparação dos métodos Controle Preditivo de Conjugado e Controle Direto de Potência em um sistema de geração utilizando gerador duplamente alimentado." In Congresso Brasileiro de Automática - 2020. sbabra, 2020. http://dx.doi.org/10.48011/asba.v2i1.1332.

Full text

Abstract:

Neste trabalho é realizada a comparação dos desempenhos dos métodos Controle Direto de Potência (conhecido na literatura por sua sigla em inglês, DPC) e Controle Preditivo de Conjugado (conhecido na literatura por sua sigla em inglês, PTC) em um sistema de geração eólica que utiliza gerador de indução duplamente alimentado. Os dois métodos são discutidos e comparados através de resultados de simulação nos regimes permanente e transitório para um gerador de potência nominal de 500 W. Será mostrado que o método DPC apresenta uma resposta dinâmica mais rápida, mas pode apresentar maior distorção harmônica nas correntes do rotor que o método PTC, dependendo da velocidade do rotor.

APA, Harvard, Vancouver, ISO, and other styles

3

Kelm, Soerge, Nadine Bock, Karen Strenge, and Reinhard Brossmer. "SYNTHETIC SIALIC ACID ANALOGUES BINDING TO SIGLECS WITH HIGH AFFINITY AND SELECTIVITY." In XXIst International Carbohydrate Symposium 2002. TheScientificWorld Ltd, 2002. http://dx.doi.org/10.1100/tsw.2002.484.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Li, L., G. A. Gusarova, M. N. Islam, and J. Bhattacharya. "Siglec-F Determines Lung Immunity Through Regulation of Macrophage Gap Junctions." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5832.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Li, Peixue, Guofang Yan, Fuyang Wang, Xuzhen Tang, and Qing Lin. "Abstract 1634: Siglec-15 knockout inhibits tumor growth in mouse model." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-1634.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Sae Lim, VS, J. Klotsche, M. Heinrich, et al. "PS1:11 The interferon biomarker siglec1 reflects disease activity in paediatric systemic lupus erythematosus." In 11th European Lupus Meeting, Düsseldorf, Germany, 21–24 March 2018, Abstract presentations. Lupus Foundation of America, 2018. http://dx.doi.org/10.1136/lupus-2018-abstract.60.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Lee, Jennifer, Moon Young Kim, and Sung-Hwan Park. "AB0532 SOLUBLE SIGLEC-5 IS A NOVEL SALIVARY BIOMARKER FOR PRIMARY SJOGREN’S SYNDROME." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.5540.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Nicoll, Gavin, Magnus Alphey, Helen Attrill, Daan van Aalten, and Paul R. Crocker. "STRUCTURE-FUNCTION STUDIES ON SIGLEC-7, AN INHIBITORY RECEPTOR OF NATURAL KILLER CELLS." In XXIst International Carbohydrate Symposium 2002. TheScientificWorld Ltd, 2002. http://dx.doi.org/10.1100/tsw.2002.381.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Läubli, Heinz, Oliver M. T. Pearce, Flavio Schwarz, et al. "Abstract 3659: Engagement of myelomonocytic siglecs by tumor-associated ligands modulates innate immune responses to cancer." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-3659.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Liu, T., Y. H. Feng, F. P. Wang, and H. Mao. "Defining the Preliminary Function of Siglec-F Expressed on Mouse Alveolar Macrophages In Vitro." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a6174.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "SIGLICA"

1

Vargas-Herrera, Hernando, Pamela Andrea Cardozo-Ortiz, Clara Lía Machado-Franco, et al. Reporte de Sistemas de Pago - Junio de 2021. Banco de la República de Colombia, 2021. http://dx.doi.org/10.32468/rept-sist-pag.2021.

Full text

Abstract:

El Banco de la República, con el Reporte de Sistemas de Pago, entrega un panorama completo de la infraestructura financiera local, siendo este un producto importante de la labor de seguimiento a dicha infraestructura. Las cifras contenidas en este reporte corresponden al año 2020, período de pandemia durante el cual las medidas de confinamiento para aliviar la tensión sobre el sistema de salud generaron para Colombia, al igual que en la mayoría de los países, una fuerte reducción de la actividad económica y el consumo. Desde el comienzo de la pandemia, la Junta Directiva del Banco de la República adoptó las decisiones necesarias para otorgar al mercado amplia liquidez en pesos y dólares, garantizar la estabilidad de los mercados, proteger el sistema de pagos y preservar la oferta de crédito. El pronunciado crecimiento de los agregados monetarios reflejó la mayor preferencia por liquidez, la cual fue atendida oportunamente por el Banco de la República. Las decisiones adoptadas se realizaron mediante diferentes operaciones, las cuales fueron compensadas y liquidadas en la infraestructura financiera. Después de la introducción, la segunda sección del presente reporte de pagos analiza la evolución y el desempeño de las diferentes infraestructuras financieras. Se destaca que el sistema de pagos de alto valor CUD registró en 2020 un mayor dinamismo que el año anterior, principalmente por el aumento de los depósitos remunerados que en promedio diario realizó la Dirección General de Crédito Público y del Tesoro Nacional (DGCPTN) con el Banco de República, así como una mayor actividad del mercado de simultáneas de deuda pública. Consecuentemente con el crecimiento de la actividad en el CUD, el Depósito Central de Valores (DCV) registró una mayor actividad por el aumento del mercado monetario de deuda pública y por las colocaciones por parte del Gobierno Nacional en el mercado primario. El valor de las operaciones compensadas y liquidadas por intermedio de la Cámara de Riesgo Central de Contraparte (CRCC) continúa creciendo, jalonado principalmente por los contratos non delivery forward (NDF) peso/dólar. Con respecto a la CRCC, es oportuno mencionar que a partir de finales del año pasado esta cámara se encarga de administrar los riesgos y de compensar y liquidar las operaciones del mercado de contado peso/dólar, debido a la fusión con la Cámara de Compensación de Divisas de Colombia (CCDC). Así mismo, a partir del último trimestre del año 2020 la CRCC se encarga de compensar y liquidar el mercado de renta variable, labor que venía desempeñando la Bolsa de Valores de Colombia (BVC). En la sección tres se entrega una visión integral de los pagos en el mercado de bienes y servicios, es decir, de las transacciones efectuadas en el circuito de personas naturales y empresas no financieras. Durante la pandemia las transferencias electrónicas inter e intrabancarias, que en su mayoría son originadas por empresas, registraron un incremento tanto en número como en valor de operaciones frente a 2019. Por su parte, los pagos con tarjetas débito y crédito originados principalmente por personas naturales mostraron un comportamiento decreciente con respecto a 2019. Los pagos realizados con cheques siguen disminuyendo, presentando una tendencia a la baja muy pronunciada en el último año. Como complemento a la información sobre transferencias electrónicas, el reporte incluye en esta sección un sombreado sobre la caracterización de la población con cuenta de ahorro y corriente, empleando los datos de la encuesta del Banco de la República sobre percepción de uso de los instrumentos de pago en 2019. Se incluye también un recuadro sobre la evolución transaccional de una billetera móvil provista por una sociedad especializada en depósitos y pagos electrónicos (Sedpe), mostrando que desde su creación a finales del año 2017 ha incremento en el número de usuarios y el valor de las transacciones, con especial velocidad durante la pandemia. Adicionalmente, se presenta un diagnóstico sobre los efectos de la pandemia en los patrones de pago de la población, fundamentado en datos sobre el uso del efectivo en circulación, sobre los pagos con instrumentos electrónicos, y sobre el consumo y la confianza del consumidor. Se concluye que el desplome en el índice de confianza del consumidor y la caída en el consumo privado dieron lugar a cambios en los patrones de pago de las personas. Las compras con tarjetas de crédito y débito disminuyeron, mientras que los pagos por bienes y servicios mediante transferencia electrónica aumentaron. Estos resultados, junto con el considerable aumento del efectivo en circulación, podrían proveer indicios a favor de un posible atesoramiento del papel moneda con motivo precaución por parte de las personas y de un mayor uso del efectivo como instrumento de pago. Se incluye, además, un recuadro que presenta los principales cambios que se introdujeron en la regulación del sistema de pagos de bajo valor en el país mediante la expedición del Decreto 1692 de diciembre de 2020. La cuarta sección se refiere a las importantes innovaciones y cambios tecnológicos que se han observado en el sistema de pagos al por menor. Se destacan cuatro temas en esta línea. El primero se constituye en un punto clave para la construcción de la infraestructura financiera de pagos inmediatos. Consiste en el diseño e implementación de los llamados esquemas superpuestos, los cuales son un desarrollo tecnológico que permite una comunicación abierta entre los diferentes agentes de la cadena de pagos, logrando una alta interoperabilidad entre diferentes proveedores de servicios de pago. El segundo tema explora los avances en el debate internacional sobre la emisión de moneda digital por parte de los bancos centrales (CBDC por su sigla en inglés), con el fin de entender su posible impacto en el sistema de pagos de bajo valor y en el uso del efectivo. El tercer tema está relacionado con nuevas formas de iniciación de pagos, tales como los códigos QR, la biometría o la tecnología de comunicación de campos cercanos (NCF por su sigla en inglés). Estos cambios, aparentemente pequeños, pueden tener efectos importantes en la experiencia del usuario con el sistema de pagos de bajo valor. El cuarto tema, finalmente, es el crecimiento de los pagos vinculados con la telefonía móvil y el internet. El reporte finaliza en la sección cinco con una reseña de dos trabajos de investigación aplicada realizados en el Banco de la República en el año 2020. El primero analiza el nivel patrimonial de la CRCC, reconociendo el rol relevante que esta infraestructura ha adquirido en la compensación y liquidación de varios mercados financieros en el país. Se exploran los requerimientos de capital para las entidades de contrapartida central establecidos en algunas jurisdicciones, se identifican los riesgos que se busca cubrir desde la perspectiva del servicio que este tipo de entidades ofrece al mercado y aquellos asociados a su actividad corporativa. Se analizan los niveles patrimoniales de la CRCC a partir de lo observado en la regulación de la Unión Europea y se concluye que la CRCC cuenta con un esquema de anillos de seguridad muy similar al observado en la experiencia internacional y que su nivel patrimonial es superior al exigido por la regulación colombiana, siendo suficiente para cubrir otros riesgos. El segundo trabajo de investigación identifica y cuantifica las fuentes que utilizan las entidades participantes en el CUD para cumplir con sus obligaciones diarias contraídas en el mercado financiero local, y con su uso como herramienta de monitoreo de la liquidez intradía en condiciones normales. Leonardo Villar Gómez Gerente General

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!